Who are Ropivacaine Ketorolac's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ropivacaine and ketorolac, Bupivacaine-Meloxicam.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ropivacaine-ketorolac.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Ropivacaine Ketorolac — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ropivacaine Ketorolac (Ropivacaine Ketorolac) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic + NSAID combination. Area: Pain Management / Anesthesia.

marketed Local anesthetic + NSAID combination Voltage-gated sodium channels (ropivacaine); COX-1/COX-2 (ketorolac) Pain Management / Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

Ropivacaine Ketorolac (Ropivacaine Ketorolac) — University of Aarhus. Ropivacaine provides local anesthesia by blocking sodium channels in nerve fibers, while ketorolac provides anti-inflammatory and analgesic effects by inhibiting cyclooxygenase enzymes.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Ropivacaine Ketorolac TARGET	Ropivacaine Ketorolac	University of Aarhus	marketed	Local anesthetic + NSAID combination	Voltage-gated sodium channels (ropivacaine); COX-1/COX-2 (ketorolac)
ropivacaine and ketorolac	ropivacaine and ketorolac	University of Aarhus	marketed	Local anesthetic + NSAID combination	Voltage-gated sodium channels (ropivacaine); COX-1 and COX-2 (ketorolac)
Bupivacaine-Meloxicam	Bupivacaine-Meloxicam	TriHealth Inc.	phase 3	Local anesthetic + NSAID combination	Voltage-gated sodium channels (bupivacaine); COX-1/COX-2 (meloxicam)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic + NSAID combination class)

University of Aarhus · 2 drugs in this class
TriHealth Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ropivacaine Ketorolac — Competitive Intelligence Brief. https://druglandscape.com/ci/ropivacaine-ketorolac. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab